Mazdutide vs Retatrutide
How Mazdutide and Retatrutide compare on research category, evidence tier, regulatory status, and reported side effects.
The verdict
Both are next-generation metabolic peptides, but they are not the same bet. Mazdutide is a GLP-1 plus glucagon dual agonist with obesity approval in China, while Retatrutide adds GIP as a third receptor and has posted the bigger trial weight-loss headlines. Mazdutide has the cleaner current approval story in its market; Retatrutide is the more powerful-looking investigational compound if the Phase 3 data holds.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Mazdutide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.